Jefferies Group LLC reaffirmed their hold rating on shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) in a research note issued to investors on Monday morning. Jefferies Group LLC currently has a $1.50 price objective on the biotechnology company’s stock.
GNMX has been the topic of several other reports. ValuEngine cut Aevi Genomic Medicine from a sell rating to a strong sell rating in a report on Friday, June 2nd. UBS AG reissued a positive rating on shares of Aevi Genomic Medicine in a report on Wednesday, May 10th.
Aevi Genomic Medicine (NASDAQ GNMX) remained flat at $1.18 during mid-day trading on Monday. The company’s stock had a trading volume of 12,747 shares. The firm’s market cap is $43.79 million. Aevi Genomic Medicine has a 52-week low of $0.98 and a 52-week high of $6.89. The company has a 50-day moving average price of $1.30 and a 200-day moving average price of $2.56.
Aevi Genomic Medicine (NASDAQ:GNMX) last released its quarterly earnings results on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by $0.02. Analysts anticipate that Aevi Genomic Medicine will post ($1.08) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/08/08/aevi-genomic-medicines-nasdaqgnmx-hold-rating-reaffirmed-at-jefferies-group-llc.html.
Several institutional investors have recently added to or reduced their stakes in GNMX. Teachers Advisors LLC purchased a new position in Aevi Genomic Medicine during the fourth quarter valued at $204,000. LMR Partners LLP purchased a new position in Aevi Genomic Medicine during the second quarter valued at $149,000. TIAA CREF Investment Management LLC boosted its position in Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 13,966 shares during the last quarter. Birchview Capital LP boosted its position in Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 20,000 shares during the last quarter. Finally, State Street Corp boosted its position in Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 46,149 shares during the last quarter. 27.97% of the stock is currently owned by hedge funds and other institutional investors.
About Aevi Genomic Medicine
Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohns disease.
Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.